NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis
Open accessThe DOI matches its Crossref record; 68 of the 72 references it cites were found in a registry or an index, and 4 are not checked yet; 6 of the 41 sources its claims cite were checked for support.
Abstract
Metabolic-associated fatty liver disease (MAFLD) is a spectrum of clinical manifestations ranging from benign steatosis to cirrhosis. A key event in the pathophysiology of MAFLD is the development of nonalcoholic steatohepatitis (NASH), which can potentially lead to fibrosis and hepatocellular carcinoma, but the triggers of MAFLD-associated inflammation are not well understood. We have observed that lipid accumulation in hepatocytes induces expression of ligands specific to the activating immune receptor NKG2D. Tissue-resident innate-like T cells, most notably γδ T cells, are activated through NKG2D and secrete IL-17A. IL-17A licenses hepatocytes to produce chemokines that recruit proinflammatory cells into the liver, which causes NASH and fibrosis. NKG2D-deficient mice did not develop fibrosis in dietary models of NASH and had a decreased incidence of hepatic tumors. The frequency of IL-17A + γδ T cells in the blood of patients with MAFLD correlated directly with liver pathology. Our findings identify a key molecular mechanism through which stressed hepatocytes trigger inflammation in the context of MAFLD.
Verified 2026-10-05 · 4 references not checked yet
Overview
CoChat Summary
TL;DR
Metabolic stress in hepatocytes induces NKG2D ligands, which are detected by liver-resident innate-like T cells—especially γδ T cells—that produce IL-17A and initiate NASH-associated inflammation and fibrosis. Genetic loss of NKG2D, γδ T cells, or hepatocyte IL-17A receptor signaling reduced fibrosis without affecting steatosis, and blood IL-17A⁺ γδ T cells correlated with human liver stiffness.
Key findings
- In human MAFLD biopsies, NKG2D ligand MICA/B was upregulated in steatotic regions (n=17), and IL-17A⁺ cells correlated with steatosis and inflammation, peaking at early NAS scores 3–5 (n=35).
- In mice, the steatosis-steatohepatitis diet (SSD) induced NKG2D ligands on lipid-loaded hepatocytes; cholesterol was most effective at inducing H60 in primary hepatocytes, and omitting cholesterol prevented inflammation in vivo.
- NKG2D deficiency (Klrk1−/−) or DAP10 deficiency (Hcst−/−) reduced fibrosis and αSMA after 16 weeks of SSD without greatly affecting steatosis; after 1 year, Klrk1−/− mice had lower ALT, NASH score, fibrosis, leukocyte infiltration, and tumor incidence versus WT (WT tumor incidence ~25%, more than two-fold reduced in Klrk1−/−).
- Fibrosis was mediated by innate-like T cells: TCRα−/−, Cd4cre Klrk1fl/fl, and Tcrd−/− mice showed reduced fibrosis, while MAIT-cell and CD1d-restricted NKT-cell manipulations did not; hepatocyte-specific IL-17A receptor deficiency (IL17raΔHep) reduced fibrosis. Blood IL-17A⁺ γδ T cells correlated with liver stiffness in MAFLD patients (n=18).
Methods
- Human liver biopsy material and blood from MAFLD patients were analyzed by histology, flow cytometry, and correlation with steatosis, NAS score, and liver stiffness measurement (LSM).
- Mice were fed normal chow, SSD, high-fat diet, high-cholesterol diet, or methionine/choline-deficient diet; genetic models included Klrk1−/−, Hcst−/−, Tcra−/−, Tcrd−/−, Cd1d−/−, Mr1−/− MAIT CAST, Ncr1cre Klrk1fl/fl, Cd4cre Klrk1fl/fl, and IL17rafl/fl crosses.
- Main analyses included RNA sequencing of liver lysates, flow cytometry, histology/immunohistochemistry, qPCR, lipidomics by LC-MS/MS, and in vitro hepatocyte and γδ T cell stimulation assays.
Limitations
- The paper states that it cannot exclude SSD feeding mediating immune activation at other sites such as adipose tissue, though hepatocyte IL-17A receptor deficiency ameliorated pathology.
- The paper notes that hepatocyte IL-17A receptor deficiency did not protect as strongly as Klrk1−/−, suggesting additional NKG2D-induced factors; whether γδ T cell-derived GM-CSF contributes remains unclear.
- The paper states that no model specifically targets genes in γδ T cells because the available TcrdCreERt2 model has poor efficiency in liver, and that DN T cells cannot be targeted alone due to lack of cell-specific markers; human data are correlative and based on relatively small biopsy/blood cohorts.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 2 Not valid · 20 Not checked · 88 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“This showed that Rorc, the transcription factor mediating IL-17A expression, is predominantly expressed by T cells (Fig. S1c).”
§ NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis > MAFLD is associated with an increase of NKG2D ligands and IL-17A-expressing cells in the human liver
What the sources say
- Could not verifycites [24] sourceExperimental — accuracy not yet measured
The section on the ob/ob mouse discusses T-lymphocyte responses and hepatic natural killer T cells, but not Rorc expression. Searches of our copy for Rorc, IL-17A, and single-cell RNA sequencing of human liver biopsies found no passage addressing whether Rorc is predominantly expressed by T cells. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Instead, tissue resident immune cells appear more likely to sense early metabolic stress and induce the inflammatory response (10).”
§ NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis > Introduction
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Introduction says inflammation from resident and infiltrating immune cells drives liver fibrosis, and the Results report that activated MAIT cells trigger inflammatory cytokine release from hepatic myofibroblasts and macrophages (page numbers unavailable). The paper does not establish that tissue-resident cells are more likely than other cells to sense early metabolic stress, or that such sensing initiates the inflammatory response. (LLM, conf=0.84)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In humans and mice, NASH is associated with type 3 inflammation, characterized by the by the production of the cytokine IL-17A, most notably by mucosal-associated invariant T (MAIT) cells and γδ T cells (11)(12)(13).”
§ NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis > Introduction
What the sources say
- Not checked yetcites [11] source
- Not checked yetcites [12] source
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
The Results section on HFD-induced NAFLD reports increased hepatic γδT-17 cells in mice and reduced steatohepatitis when γδ T cells are absent; the Discussion identifies these cells as a main source of IL-17A. The paper does not establish the claimed association in humans with NASH or identify MAIT cells as a notable IL-17A source in this setting. Page numbers are unavailable in our copy. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“However, TCR triggering alone is typically insufficient for the full activation of these cells (15)”
§ NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis > Introduction
What the sources say
- Could not verifycites [15] sourceExperimental — accuracy not yet measured
The paper’s introductory passage (section labeled Abstract; page unavailable) says some unconventional T cells may be activated independently of the TCR by cytokines or NKG2D ligands. Its DETC experiments describe activation following NKG2D-ligand induction, but do not test whether TCR triggering alone is typically insufficient for full activation. Searched for TCR-only stimulation and NKG2D costimulation. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After 2 weeks of SSD feeding, steatotic cells showed significantly more expression of NKG2D ligands than hepatocytes isolated from NCD-fed controls by NKG2D-Fc staining (Fig. 2j).”
§ NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis > Lipid accumulation in murine hepatocytes induces upregulation of NKG2D ligands
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
48 more claims
Create a free account to see all 114 claims and to verify the 35 references still open.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 46
- The quote only partly states this claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although hepatic γδ T cells promote IL-17 release in mouse models of liver fibrosis, and therefore indicate a profibrogenic function (76, 77)”
From Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy (2024) · doi:10.1146/annurev-pharmtox-020524-012013 · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis > One Sentence Summary
“(g, h) WT and Tcrd -/-(T cell receptor α-chain deficient) mice were fed an NCD or an SSD diet for 16 weeks (n=4-10).”
§ NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis > Liver fibrosis in the context of NASH is mediated by innate-like T cells
“we made use of TCRδ -/-mice, which lack all γδ T cells.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis > One Sentence Summary
“(e) IL17ra fl/fl and Lys Cre IL7ra fl/fl (IL17ra ΔMφ ) littermates were fed an NCD or an SSD diet for 16 weeks.”
§ NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis > NKG2D mediates liver fibrosis through IL-17A induction
“First, we crossed IL17ra fl/fl mice with lysozyme Cre (Lys Cre ) animals to eliminate the IL-17A receptor in macrophages (IL17ra ΔMφ ).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis > One Sentence Summary
“(c) WT and Tcra -/-(T cell receptor δ-chain deficient) mice were fed an NCD or an SSD diet for 16 weeks.”
§ NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis > Liver fibrosis in the context of NASH is mediated by innate-like T cells
“Mice with genetic deficiency for the α-chain of the TCR were placed on SSD, and collagen deposits were quantified after 16 weeks.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis > Liver fibrosis in the context of NASH is mediated by innate-like T cells
“Further analysis revealed that all NKG2D-expressing cells also increased in absolute numbers upon two weeks of SSD feeding, relative to NCD-fed controls (Fig. S4b).”
§ NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis > NKG2D-signaling drives inflammation in the context of NASH
“The numbers of NKT cells remained comparable between SSD-and NCD-fed mice in the entire experiment.”
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
The IL-17 Family of Cytokines in Health and Disease
McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.021 · Cited by 1,443
Wong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, H. L.-Y., Le Bail, B., Choi, P. C.-L., Kowo, M., Chan, A. W.-H., Merrouche, W., et al. (2010) · Hepatology · doi:10.1002/hep.23312 · Cited by 1,322
A human liver cell atlas reveals heterogeneity and epithelial progenitors
Aizarani, N., Saviano, A., Sagar, Mailly, L., Durand, S., Herman, J. S., Pessaux, P., Baumert, T. F., & Grün, D. (2019) · Nature · doi:10.1038/s41586-019-1373-2 · Cited by 1,147
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease
Onishi, R. M., & Gaffen, S. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03240.x · Cited by 894
Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability
Lee, J. S., Tato, C. M., Joyce-Shaikh, B., Gulen, M. F., Cayatte, C., Chen, Y., Blumenschein, W. M., Judo, M., Ayanoglu, G., McClanahan, T. K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.003 · Cited by 760
Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research
Anstee, Q. M., & Goldin, R. D. (2006) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2006.00465.x · Cited by 714
Wolf, M. J., Adili, A., Piotrowitz, K., Abdullah, Z., Boege, Y., Stemmer, K., Ringelhan, M., Simonavicius, N., Egger, M., Wohlleber, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.003 · Cited by 678
Research works printed but not linked: 1
- M. Sasso, M. Beaugrand, V. De Ledinghen, C. Douvin, P. Marcellin, R. Poupon, L. Sandrin, V. Miette, Ultrasound Med. Biol. 362010), 1825–1835.
Cited by
Molecular mechanisms in MASLD/MASH-related HCC
Wang, X., Zhang, L., & Dong, B. (2025) · Hepatology · doi:10.1097/hep.0000000000000786 · Cited by 169
Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
Kuchay, M. S., Choudhary, N. S., & Ramos‐Molina, B. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00951.2024 · Cited by 115
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
He, Y., Chen, Y., Qian, S., van Der Merwe, S., Dhar, D., Brenner, D. A., & Tacke, F. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01307-5 · Cited by 81
“IL-17A then induces hepatocytes to release chemokines, which recruit proin fl amma-tory myeloid cells into the liver [86].”
The “Domino effect” in MASLD: The inflammatory cascade of steatohepatitis
Mladenić, K., Lenartić, M., Marinović, S., Polić, B., & Wensveen, F. M. (2024) · European Journal of Immunology · doi:10.1002/eji.202149641 · Cited by 98
Self-citationImmunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy
(2024) · doi:10.1146/annurev-pharmtox-020524-012013 · Cited by 64
MAFLD as part of systemic metabolic dysregulation
Zhao, J., Liu, L., Cao, Y., Gao, X., Targher, G., Byrne, C. D., Sun, D., & Zheng, M. (2024) · Hepatology International · doi:10.1007/s12072-024-10660-y · Cited by 73
Inflammation in MASLD progression and cancer
Kim, Y. S., Park, Y., Rho, H., Yao, T., Gao, B., & Hwang, S. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101414 · Cited by 75
The immunology of sickness metabolism
Wensveen, F. M., Šestan, M., & Polić, B. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01192-4 · Cited by 36
Self-citationŠestan, M., Mikašinović, S., Benić, A., Wueest, S., Dimitropoulos, C., Mladenić, K., Krapić, M., Hiršl, L., Glantzspiegel, Y., Rasteiro, A., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01848-3 · Cited by 29
Self-citationÇebi, M., & Yilmaz, Y. N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1445634 · Cited by 30
Su, L., Bu, J., Yu, J., Jin, M., Meng, G., & Zhu, X. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70066 · Cited by 28
Liver receptor homolog-1 (NR5A2) orchestrates hepatic inflammation and TNF-induced cell death
Lambrecht, R., Delgado, M. E., Gloe, V., Schuetz, K., Plazzo, A. P., Franke, B., Phan, T. S., Fleming, J. R., Mayans, O. M., & Brunner, T. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113513 · Cited by 23
Defective autophagy in CD4 T cells drives liver fibrosis via type 3 inflammation
Sayegh, R. A., Wan, J., Caër, C., Azoulai, M., Gasperment, M., Baweja, S., Chouillard, M.-A., Kandiah, J., Cadoux, M., Mabire, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59218-y · Cited by 22
Pathogenesis of metabolic dysfunction-associated steatotic liver disease and donor liver damage
Gou, C., Zhang, W., Xu, H., Zhang, H., Ding, R., & Zhang, X. (2025) · iLiver · doi:10.1016/j.iliver.2025.100195 · Cited by 24
Cheu, J. W., & Wong, C. C. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000516 · Cited by 24
Zarlashat, Y., Ghaffar, A., Guerra, F., & Picca, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167836 · Cited by 21
Yang, F., Wang, W., Qiu, F., Qing, R., Gao, Q., Yan, X., Wu, D., Hui, H., Dang, R., Jiang, G., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-025-01436-1 · Cited by 9
The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis
Chen, X., Wu, C. F., Tang, F., Zhou, J., Mo, L., Li, Y., & He, J. (2025) · Advanced Science · doi:10.1002/advs.202505067 · Cited by 15
Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets
Qian, S., Wang, X., Chen, Y., Zai, Q., & He, Y. (2024) · Seminars in Liver Disease · doi:10.1055/a-2338-9261 · Cited by 7
The Metabolic Regulation of the NKG2D-Positive NK and T Cells and Their Role in Disease Progression
Tang, J., Lu, Y., Chen, M., Wu, Q., Li, Y., Qin, Y., Liang, S., Luo, S., & Liu, K. (2025) · Biomolecules · doi:10.3390/biom15111506 · Cited by 8
Advanced strategies based on nanomedicine for Liver fibrosis treatment
Zhang, L., Liu, T., Shen, H., Liu, B.-H., Mei, Y., Liu, Y., Chen, S., Ma, X., He, C., Hu, T., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126437 · Cited by 7
Hepatic iNKT cells facilitate colorectal cancer metastasis by inducing a fibrotic niche in the liver
Nater, M., Brügger, M. D., Cecconi, V., Pereira, P., Forni, G., Köksal, H., Dimakou, D., Herbst, M., Calvanese, A. L., Lucchiari, G., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112364 · Cited by 7
Lactylation‐Driven YTHDC1 Alleviates MASLD by Suppressing PTPN22‐Mediated Dephosphorylation of NLRP3
Zhang, F., Zeng, L.-H., Zou, K., Lin, K., Yao, F., Song, J., Zhang, S., Feng, H., Yang, Z., Wang, C., et al. (2025) · Advanced Science · doi:10.1002/advs.202510192 · Cited by 9
Sbierski‐Kind, J., Cautivo, K. M., Nilsson, J., Wagner, J., Dahlgren, M. W., Ewing-Crystal, N. A., Krasilnikov, M., Mroz, N. M., Ganslmeier, M., Lizama, C. O., et al. (2026) · Science Advances · doi:10.1126/sciadv.aea6805 · Cited by 3
The immunometabolic nature of MASH: framing immune cells within metabolic dysfunction
González-Serrano, S., Onoiu, A.-I., Jiménez-Franco, A., Cambra-Cortés, V., Camps, J., & Joven, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1797949 · Cited by 4
Li, X., Jin, K., Fang, J., Ma, X., He, J., Lu, A., Jia, Z., & Shi, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835197 · Cited by 4
Arai, J., Okumura, A., Kimoto, S., Sakamoto, K., Kitada, T., Kitano, R., Inoue, T., Nishimura, S., Inden, N., Muraki, Y., et al. (2025) · Hepatology International · doi:10.1007/s12072-025-10800-y · Cited by 5
Immune cells in metabolic associated fatty liver disease: Global trends and hotspots (2004-2024)
Qi, W., Zheng, S., Li, S., Wang, W., Wang, Q., Liu, Q.-Y., Li, X., Zhang, J., Gan, D., Ye, Y., et al. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i3.103327 · Cited by 7
Yang, J., Guo, L., Ren, S., Lai, Q., Yang, S., Wu, Y., Ying, S., Meng, Y., & Li, Q. (2026) · Food Research International · doi:10.1016/j.foodres.2026.119293 · Cited by 2
Identification of Key Genes Related to Both Lipid Metabolism Disorders and Inflammation in MAFLD
Dai, X., Hu, Y.-H., Zhang, K., Wang, B., Zhang, J., & Cao, H. (2025) · Biomedicines · doi:10.3390/biomedicines13092211 · Cited by 1
Immune microenvironment and immunotherapy strategies in MAFLD-related hepatocellular carcinoma
Han, H.-N., Ma, J.-H., Wang, J.-B., & Liu, Y. (2025) · Hepatoma Research · doi:10.20517/2394-5079.2025.54 · Cited by 1
Diverse immunological roles of liver‐resident immune cells in liver diseases
Fan, Z., Li, X., Jiang, P., Teng, D., & Cai, J. (2026) · Precision Medical Sciences · doi:10.1002/prm2.70026 · Cited by 1
Li, X., Lin, H., Liang, J., Jin, X., Shen, T., Hu, Y., & Huang, H. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00430-w · Cited by 1
Low Hepatic CEACAM1 Tethers Metabolic Dysfunction Steatohepatitis to Atherosclerosis
Khoury, S. E., Harake, S. N. A., Youssef, T., Risk, C. E., Helou, N., Doumet, N. M., Aramouni, K., Azar, S. T., Najjar, S. M., & Ghadieh, H. E. (2025) · Livers · doi:10.3390/livers5030034 · Cited by 1
Liver immunology: Biological role and clinical significance
Kotlyarov, S. N. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.107541 · Cited by 6
Zhao, C., Ren, H. W., Ke, Q., Chen, Q., He, J., Tian, R., Pan, H., & Liu, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1770733 · Cited by 1
Cuculić, M. T., Sergo, D., Kavazović, I., Peršić, V., Wensveen, F. M., & Wensveen, T. T. (2026) · Research Square · doi:10.21203/rs.3.rs-9020037/v1
Self-citationLimongelli, A., Bozzano, F. M., Hajabbas-Farshchi, A., Bellucci, M., Bavastro, M., Castellano, C., Pesce, G., Antonini, F., Incensi, A., Giannoccaro, M. P., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1752120
Juan-García, C. A. S., Escamilla, R. I., Cruz-Romero, L., Hernández-Silva, C. D., Fernández-Quezada, D., la Cruz-Mosso, U. D., Pereira-Suárez, A. L., Haramati, J., Ramírez-López, I. G., Macías‐Barragán, J., et al. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i3.115111
Breaking the metabolo-immune cycle in primary biliary cholangitis for therapeutic benefit
Yan, S., Wang, H., Du, S., Li, Y., Yang, D., Xu, M., & Jin, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1766177
Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy
He, W., & McMichael, A. J. (2026) · MedComm · doi:10.1002/mco2.70742 · Cited by 1
Thurairajah, B., Westfall, S., Chiggiato, L., Keogh, L., Sinha, A., Olsen, K. A., Gavino, C., Tafesse, Y., Moens, E., Lypaczewski, P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.28.721483
Depletion of NAT10 in T cells attenuates metabolic dysfunction–associated steatohepatitis in mice
Yang, Y., Lu, J., Ma, M., Zhou, J., Wang, E., Lu, Y., Dai, Z., Zhou, B., & Li, Y. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000973
Metadata
- Authors
- Marinović, S., Lenartić, M., Mladenić, K., Šestan, M., Kavazović, I., Benić, A., Krapić, M., Rindlisbacher, L., Cokarić Brdovčak, M., Sparano, C., Litscher, G., Turk Wensveen, T., Mikolašević, I., Fučkar Čupić, D., Bilić-Zulle, L., Steinle, A., Waisman, A., Hayday, A., Tugues, S., Becher, B., Polić, B., & Wensveen, F. M.
- Affiliations
- University of Rijeka (HR)
- University of Zurich (CH)
- Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
- Department of Internal Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
- Department of General Pathology and Pathological Anatomy, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
- Klinički Bolnički Centar Rijeka (HR)
- Goethe University Frankfurt (DE)
- Johannes Gutenberg University Mainz (DE)
- King's College London (GB)
- Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland.
- Corresponding author
- Marinović, Sonja
- Lenartić, Maja
- Mladenić, Karlo
- Polić, Bojan
- Wensveen, Felix M.
- ORCID
- Marinović, Sonja
- Lenartić, Maja
- Mladenić, Karlo
- Šestan, Marko
- Kavazović, Inga
- Benić, Ante
- Krapić, Mia
- Rindlisbacher, Lukas
- Sparano, Colin
- Litscher, Gioana
- Mikolašević, Ivana
- Fučkar Čupić, Dora
- Bilić-Zulle, Lidija
- Steinle, Aleksander
- Waisman, Ari
- Hayday, Adrian
- Tugues, Sonia
- Becher, Burkhard
- Polić, Bojan
- Wensveen, Felix M.
- Venue
- Science Immunology
- Published
- 2023-09-29
- Volume
- 8
- Issue
- 87
- Pages
- eadd1599-eadd1599
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC7615627
- OpenAlex
- W4387164921
- Cited by
- 43
- References
- 72
- Citations by year
- 2026: 15 · 2025: 17 · 2024: 10 · 2023: 1
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by)
- Funders
- Wellcome Trust (CC2012)
- Francis Crick Institute (CC2012)
- Cancer Research UK (CC2012)
- Hrvatska Zaklada za Znanost (IP-CORONA-2020-04, IP-2016-06-8027, IPCH-2020-10-8440, IP-2016-06-9306, IP-2020-02, IP-CORONA-2020-04-2045, IP-2020-02-7928)
- National Institutes of Health (KK.01.1.1.01.0006, 2020-02)
- European Regional Development Fund (-KK.01.1.1.01, KK.01.1, KK.01.1.1.01.0006)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- NKG2D, nonalcoholic steatohepatitis, liver fibrosis, metabolic-associated fatty liver disease, γδ T cells, innate-like T cells, IL-17A, lipid accumulation, hepatocyte inflammation, chemokine recruitment, hepatocellular carcinoma
- MeSH terms
- Animals, Humans, Inflammation, Liver Cirrhosis, T-Lymphocytes, Interleukin-17, Hepatocytes, Mice, NK Cell Lectin-Like Receptor Subfamily K, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.